NCT00585377View on ClinicalTrials.gov

Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Cancer
Interventions
DRUG

Bevacizumab and Erlotinib

Erlotinib 150 mg/day orally plus bevacizumab 15 mg/kg intravenously every 21 days

Trial Locations (1)

84112

University of Utah, Salt Lake City

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of Utah

OTHER